세계의 항비만제 시장

Global Anti-Obesity Drugs Market to Reach US$5.4 Billion by 2030

The global market for Anti-Obesity Drugs estimated at US$3.3 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$4.9 Billion by the end of the analysis period. Growth in the OTC Drugs segment is estimated at 11.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$913.3 Million While China is Forecast to Grow at 7.9% CAGR

The Anti-Obesity Drugs market in the U.S. is estimated at US$913.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$812.2 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global Anti-Obesity Drugs Market - Key Trends and Drivers Summarized

What Are Anti-Obesity Drugs and How Do They Work?

Anti-obesity drugs are medications designed to help individuals lose weight and maintain weight loss by targeting various physiological pathways involved in hunger, satiety, and fat absorption. These drugs function through different mechanisms such as appetite suppression, increasing feelings of fullness, reducing fat absorption from the diet, and enhancing energy expenditure. Commonly prescribed anti-obesity drugs include orlistat, which inhibits fat absorption in the intestines, and medications like liraglutide and phentermine-topiramate, which act on the central nervous system to reduce appetite. These drugs are typically prescribed for individuals with a Body Mass Index (BMI) of 30 or higher, or for those with a BMI of 27 or higher who have weight-related health conditions such as hypertension, type 2 diabetes, or dyslipidemia. The goal of these medications is to assist patients in achieving a sustainable weight loss that contributes to overall health improvement.

How Are Anti-Obesity Drugs Utilized in Clinical Practice?

In clinical practice, anti-obesity drugs are part of a comprehensive weight management plan that includes lifestyle modifications such as diet, exercise, and behavioral therapy. Physicians typically evaluate a patient's health status, weight history, and weight-loss goals before prescribing these medications. The effectiveness and safety of anti-obesity drugs are closely monitored through regular follow-up appointments. Patients are often advised to adhere to a reduced-calorie diet and increase physical activity to maximize the benefits of the medication. In some cases, anti-obesity drugs are used as an adjunct to bariatric surgery, either preoperatively to reduce surgical risks or postoperatively to maintain weight loss. The integration of pharmacotherapy with lifestyle interventions aims to achieve long-term weight management and mitigate the health risks associated with obesity, such as cardiovascular disease, type 2 diabetes, and certain cancers.

What Are the Recent Innovations in Anti-Obesity Drug Development?

The field of anti-obesity drug development has seen significant advancements driven by a deeper understanding of the biological mechanisms underlying obesity. Recent innovations include the development of GLP-1 receptor agonists like semaglutide, which mimic the effects of the gut hormone GLP-1 to enhance satiety and reduce appetite. Semaglutide has shown promising results in clinical trials, with significant weight loss outcomes compared to existing therapies. Another exciting area of research is the development of dual agonists that target multiple metabolic pathways simultaneously, such as tirzepatide, which acts on both GLP-1 and GIP receptors to regulate glucose and energy balance. Additionally, novel drug delivery systems, including long-acting injectables and oral formulations, are being explored to improve patient adherence and convenience. Advances in genomics and personalized medicine are also paving the way for more tailored obesity treatments, allowing for more precise targeting of specific patient populations based on genetic and metabolic profiles.

What Factors Are Driving the Growth in the Anti-Obesity Drugs Market?

The growth in the anti-obesity drugs market is driven by several factors. The rising prevalence of obesity worldwide, exacerbated by sedentary lifestyles and unhealthy dietary habits, is a primary driver, creating a substantial demand for effective weight management solutions. Technological advancements in drug development, including novel mechanisms of action and innovative delivery methods, are enhancing the efficacy and safety profiles of anti-obesity medications, attracting more healthcare providers and patients. Increased awareness of the health risks associated with obesity, coupled with growing acceptance of pharmacotherapy as a viable weight management option, is also contributing to market growth. Regulatory approvals and favorable reimbursement policies in several regions are facilitating the accessibility and affordability of these drugs. Furthermore, the expanding research on the metabolic and genetic factors influencing obesity is leading to the development of more targeted and personalized treatments, further boosting the market. Collectively, these factors underscore the dynamic expansion of the anti-obesity drugs market, reflecting its critical role in addressing the global obesity epidemic.

SCOPE OF STUDY:

The report analyzes the Anti-Obesity Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Prescription Drugs, OTC Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 23 Featured) -

• Eisai Co. Ltd. (Japan)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline Plc
• Novo Nordisk A/S (Denmark)
• Rhythm Pharmaceuticals (US)
• VIVUS Inc. (US)

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Anti-Obesity Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Obesity Throws the Spotlight on Anti-Obesity Drugs
  • Advances in Pharmacotherapy Propel Growth in Anti-Obesity Drugs Market
  • Increasing Awareness of Obesity-Related Health Risks Expands Addressable Market Opportunity
  • Development of Novel Drug Formulations Strengthens Business Case for Anti-Obesity Treatments
  • Growing Adoption of Combination Therapies Generates Demand for Comprehensive Solutions
  • Technological Innovations in Drug Delivery Systems Drives Adoption of Anti-Obesity Drugs
  • Expansion of Weight Management Programs Sustains Growth in Anti-Obesity Drugs Market
  • Increasing Focus on Personalized Medicine Accelerates Market Demand
  • Regulatory Approvals for New Drugs Spurs Market Growth
  • Integration with Digital Health Platforms Propels Market Growth for Anti-Obesity Treatments
  • Growing Need for Non-Invasive Treatments Drives Adoption of Anti-Obesity Drugs
  • Expansion of Lifestyle-Related Health Initiatives Generates Demand for Effective Treatments
  • Development of Targeted Therapies for Specific Patient Populations Expands Market Opportunities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anti-Obesity Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for OTC Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for OTC Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 8: USA Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 9: USA 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• CANADA
  • TABLE 10: Canada Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 11: Canada 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• JAPAN
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 12: Japan Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 13: Japan 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• CHINA
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 14: China Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 15: China 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• EUROPE
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 16: Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 17: Europe 6-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 18: Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 19: Europe 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• FRANCE
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 20: France Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: France 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• GERMANY
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 22: Germany Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 23: Germany 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• ITALY
  • TABLE 24: Italy Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Italy 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• UNITED KINGDOM
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 26: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: UK 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Rest of Europe 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• ASIA-PACIFIC
  • Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Asia-Pacific 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Rest of World 6-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2025 & 2030

IV. COMPETITION